Biotron’s BIT225 reverses HIV-induced impairment of the immune system
Australian viral disease specialist Biotron (ASX: BIT) presented data at the 20th International AIDS Conference, underway in Melbourne, Australia, showing that its BIT225 is able to reverse HIV-induced impairment of the immune system.
HIV causes immune activation and inflammation which can have the effect of advanced aging and neurological dysfunction. This immune activation can be detected by specific markers in the blood.
Blood taken from HIV-infected patients treated for 10 days with BIT225 showed a significant reduction in inflammatory marker sCD163, which is associated with cells known as macrophages. By the end of treatment with BIT225, sCD163 had returned to pre-treatment levels, while samples from placebo-treated controls showed unchanged sCD163 levels throughout the study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze